drugset / Trial / NCT00130962

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

NCT00130962

Phase 2 Completed 60 enrolled AlgoRx Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.

Timeline

Start
2004-09
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule Other

Indications